Issues related to healthcare legislation, drug pricing generally including the 340B Drug Discount Program; issues and policies relating to the FDA including pharmaceutical and bio similars; general education about policies impacting pharmaceutical development, approval, reimbursement and pricing; issues related to health equity, diversity, and inclusion in clinical trials; issues related to public health preparedness and response
Issues related to Medicare and Medicaid Coverage and reimbursement; 340 B Drug Discount Program; drug pricing issues generally
Duration: January 1, 2016
to
present
General Issues: Health Issues , Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Pharmacy , Taxation/Internal Revenue Code , Copyright/Patent/Trademark , Budget/Appropriations , Trade (Domestic & Foreign)
Spending: about $1,060,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Matthew Berzok LD and Chief Counsel, Rep. Bart Stupak, LA Rep. Peter Deutsch
LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch
LA and Chief Counsel, Rep. Bart Stupak; LA Rep. Peter Deutsch
Nick Kolovos LA and Counsel, Rep. Anna Eshoo
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Rivendell Group LLP lobbied for Genentech , earning $40,000. The report was filed on April 20.
Original Filing: 301567767.xml
Lobbying Issues
Issues related to healthcare legislation, drug pricing generally including the 340B Drug Discount Program; issues and policies relating to the FDA including pharmaceutical and bio similars; general education about policies impacting pharmaceutical development, approval, reimbursement and pricing; issues related to health equity, diversity, and inclusion in clinical trials; issues related to public health preparedness and response
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid Coverage and reimbursement; 340 B Drug Discount Program; drug pricing issues generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Rivendell Group LLP lobbied for Genentech , earning $40,000. The report was filed on Jan. 22.
Original Filing: 301540763.xml
Lobbying Issues
HCR -Issues related to healthcare legislation, drug pricing generally including and the 340B Drug Discount Program; issues and policies relating to the FDA including biopharmaceutical development and biosimilars; general education about policies impacting pharmaceutical development, approval, reimbursement and pricing;
issues related to health equity, diversity, and inclusion in clinical trials; issues related to public health preparedness and response.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; 340B Drug Discount Program; drug pricing generally.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Rivendell Group LLP lobbied for Genentech , earning $40,000. The report was filed on Oct. 23, 2023.
Original Filing: 301517201.xml
Lobbying Issues
Issues relating to drug pricing; the 340B Drug Discount Program; clinical diversity; patient assistance and access; issues and policies impacting pharmaceutical development and pricing generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to drug pricing generally; the 340B Drug Discount Program, and Medicare and Medicaid coverage and reimbursement.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Rivendell Group LLP lobbied for Genentech , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301485791.xml
Lobbying Issues
Issues relating to 340B drug discount program; drug pricing; public health preparedness; healthcare legislation generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
issues related to Medicare and Medicaid coverage and reimbursement; 340B drug discount program; drug pricing issues generally
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Rivendell Group LLP lobbied for Genentech , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301468030.xml
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing
Issues and legislation relating to the development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives.
General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to healthcare legislation
Issues related to health equity and clinical trial diversity
Issues relating to privacy and securing the data of and personal information of consumers
Issues relating to medical research data
Issues related to public health preparedness and response
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; the 340B Drug Discount Program; drug pricing
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Rivendell Group LLP lobbied for Genentech , earning $40,000. The report was filed on Jan. 21, 2023.
Original Filing: 301444039.xml
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
Funding for flu preparedness and the SNS.
Issues relating to privacy and securing medical research data and personal health information of patients/consumers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
Funding for flu preparedness and the SNS.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Rivendell Group LLP lobbied for Genentech , earning $40,000. The report was filed on Oct. 21, 2022.
Original Filing: 301420256.xml
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
The potential inclusion of these and other healthcare policies in reconciliation legislation, "Build Back Better" HR 5376
Funding for flu preparedness and the SNS.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
The potential inclusion of these and other healthcare policies in reconciliation legislation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on July 22, 2022.
Original Filing: 301397187.xml
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
The potential inclusion of these and other healthcare policies in reconciliation legislation, "Build Back Better" HR 5376
Funding for flu preparedness and the SNS.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
The potential inclusion of these and other healthcare policies in reconciliation legislation.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on April 22, 2022.
Original Filing: 301373071.xml
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
The potential inclusion of these and other healthcare policies in reconciliation legislation, "Build Back Better" HR 5376
Funding for flu preparedness and the SNS.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
The potential inclusion of these and other healthcare policies in reconciliation legislation.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Jan. 22, 2022.
Original Filing: 301339458.xml
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
Issues relating to privacy and securing the data of and personal information of consumers. The potential inclusion of these and other healthcare policies in reconciliation legislation, "Build Back Better" HR 5376.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
Issues relating to privacy and securing the data of and personal information of consumers. The potential inclusion of these and other healthcare policies in reconciliation legislation.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Oct. 20, 2021.
Original Filing: 301314208.xml
Lobbying Issues
Issues related to the 340B Drug Discount Program; drug pricing; and general education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to diversity in clinical trials.
Issues relating to privacy and securing the data of and personal information of consumers. The potential inclusion of these and other healthcare policies in reconciliation legislation.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
2nd Quarter, 2021
In Q2, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on July 12, 2021.
Original Filing: 301275327.xml
Lobbying Issues
Issues related to healthcare legislation generally, including drug pricing, the 340B Drug Discount Program, and clinical diversity.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement, drug pricing, the 340B Drug Discount Program, and issues related to the International Pricing Index for Medicare Part B and general reference pricing.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on April 20, 2021.
Original Filing: 301268355.xml
Lobbying Issues
Issues related to drug pricing, including International Pricing Index and Most Favored Nation proposals; issues related to Medicare and Medicaid coverage and reimbursement; 340B drug discount programs; legislation related to preparedness and response to COVID.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, including International Pricing Index and Most Favored Nation proposals; drug pricing; 340B.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Jan. 21, 2021.
Original Filing: 301244167.xml
Lobbying Issues
Issues related to drug pricing, including International Pricing Index and Most Favored Nation proposals; issues related to Medicare and Medicaid coverage and reimbursement; CARES Act; legislation related to preparedness and response to coronavirus; 340B drug discount program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, including International Pricing Index and Most Favored Nation proposals; issues related to Medicare and Medicaid coverage and reimbursement; drug pricing, importation and manufacturing; 340B.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Oct. 20, 2020.
Original Filing: 301224070.xml
Lobbying Issues
Issues related to drug pricing, including International Pricing Index proposals; issues related to Medicare and Medicaid coverage and reimbursement; CARES Act; legislation related to preparedness and response to coronavirus; Strategic National Stockpile funding and oversight; 340B drug discount program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, including International Pricing Index proposals; issues related to Medicare and Medicaid coverage and reimbursement; drug pricing, importation and manufacturing; 340B.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on July 20, 2020.
Original Filing: 301196059.xml
Lobbying Issues
Issues related to drug pricing, including International Pricing Index proposals; issues related to Medicare and Medicaid coverage and reimbursement; CARES Act; legislation related to preparedness and response to coronavirus; Strategic National Stockpile funding and oversight; 340B drug discount program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, including International Pricing Index proposals; issues related to Medicare and Medicaid coverage and reimbursement; drug pricing, importation and manufacturing; 340B.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301177452.xml
Lobbying Issues
Issues related to drug pricing, including International Pricing Index proposals; issues related to Medicare and Medicaid coverage and reimbursement; healthcare legislation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, including International Pricing Index proposals; issues related to Medicare and Medicaid coverage and reimbursement; drug pricing and importation.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Jan. 20, 2020.
Original Filing: 301121886.xml
Lobbying Issues
Issues related to drug pricing, issues related to Medicare and Medicaid coverage and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, including International Pricing Index proposals; issues related to Medicare and Medicaid coverage and reimbursement.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301074433.xml
Lobbying Issues
Issues related to drug pricing, issues related to Medicare and Medicaid coverage and reimbursement.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
2nd Quarter, 2019
In Q2, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on July 22, 2019.
Original Filing: 301059229.xml
Lobbying Issues
Issues related to drug pricing, including H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; issues related to Medicare and Medicaid coverage and reimbursement.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
1st Quarter, 2019
In Q1, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on April 19, 2019.
Original Filing: 301031299.xml
Lobbying Issues
Issues related to drug pricing, including H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; issues related to Medicare and Medicaid coverage and reimbursement.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
4th Quarter, 2018
In Q4, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Jan. 22, 2019.
Original Filing: 301014916.xml
Lobbying Issues
issues and legislation relating to 340B drug discount program; issues relating to drug pricing; S. 2582 the Pandemic and All-Hazards Preparedness and Innovation Act of 2018 (PAHPA), H.R. 6378 - to reauthorize certain programs under the Pandemic and All - Hazards Preparedness Reauthorization Act -- U.S. Senate and House of Representatives
Agencies Lobbied
U.S. Senate
Lobbying Issues
MMM - issues and legislation relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and reimbursement; issues relating to drug pricing; issues related to Part D Medicare Program including coverage gap and other offsets - U.S. Senate and House of Representatives
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2582 the Pandemic and All-Hazards Preparedness and Innovation Act of 2018 (PAHPA), H.R. 6378 - to reauthorize certain programs under the Pandemic and All - Hazards Preparedness Reauthorization Act -- U.S. Senate and House of Representatives
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
In Q3, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990368.xml
Lobbying Issues
issues and legislation relating to 340B drug discount program; issues relating to drug pricing; the Pandemic and All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
MMM - issues and legislation relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and reimbursement
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on July 20, 2018.
Original Filing: 300975065.xml
Lobbying Issues
issues and legislation relating to 340B drug discount program; issues relating to drug pricing; the Pandemic and All-Hazards Preparedness Act (PAHPA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
MMM - issues and legislation relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and reimbursement
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on April 20, 2018.
Original Filing: 300952866.xml
Lobbying Issues
HR 4710, 340B Pause Act, and issues relating generally to the 340B Drug Discount Program; issues relating to drug pricing policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 4710, 340B Pause Act and other issues relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and a reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934000.xml
Lobbying Issues
Legislation impacting pharmaceutical development, pricing and reimbursement; Right to Try legislation; Prescription Drug User Fee Act (PDUFA); Drug pricing under 340B program and drug pricing issues generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Drug pricing under 340B program and drug pricing issues generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to drug pricing; issues relating to Right to Try.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2017
In Q3, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Oct. 20, 2017.
Original Filing: 300912020.xml
Lobbying Issues
Legislation impacting pharmaceutical development, pricing and reimbursement; S. 204/HR 878 Tricket Wendler Right to Try Act; Prescription Drug User Fee Act (PDUFA); Drug pricing under 340B program and drug pricing issues generally; Legislation related to repeal and replace of the Affordable Care Act (H.R. 1628 American Healthcare Act of 2017)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Drug pricing under 340B program and drug pricing issues generally; Legislation related to repeal and replace of the Affordable Care Act (H.R. 1628 American Healthcare Act of 2017)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to drug pricing; issues relating to right to try
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2017
In Q2, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on July 20, 2017.
Original Filing: 300896182.xml
Lobbying Issues
Drug pricing under 340B program and drug pricing issues generally; Legislation related to repeal and replace of the Affordable Care Act (H.R. 1628 American Healthcare Act of 2017); PDUFA
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
1st Quarter, 2017
In Q1, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on April 19, 2017.
Original Filing: 300868972.xml
Lobbying Issues
Drug pricing under 340B program and drug pricing issues generally; Legislation related to repeal and replace of the Affordable Care Act (H.R. 1628 American Healthcare Act of 2017); PDUFA
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
4th Quarter, 2016
In Q4, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Jan. 20, 2017.
Original Filing: 300852679.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Drug pricing under 340B program;
Cancer Patient Protection;
Ongoing issues related to the implementation of the Affordable Care Act;
Reimbursement and patient access issues associated with CMMI Medicare Part B Drug Payment Model proposal and demo project; Vice President Cancer Moon Shot Initiative
Agencies Lobbied
U.S. Senate
Lobbying Issues
Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program;
Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
Reimbursement and patient access issues associated with CMMI proposed Medicare Part B Drug Payment Model
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834740.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
Drug pricing under 340B program;
Cancer Patient Protection;
Ongoing issues related to the implementation of the Affordable Care Act;
Comparative effectiveness research, and FDA approval of follow-on biologics; Reimbursement and patient access issues associated with CMMI Medicare Part B Drug Payment Model proposal and demo project; Vice President Cancer Moon Shot Initiative
Agencies Lobbied
U.S. Senate
Lobbying Issues
Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program;
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement;
Issues relating to Prescription Drug User Fee Act and ASP +6;
Issues related to comparative effectiveness and follow-on biologics;
Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs;
Reimbursement and patient access issues associated with CMMI proposed Medicare Part B Drug Payment Model
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6 and Part B Demo; issues related to comparative effectiveness and follow-on biologics;
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on July 20, 2016.
Original Filing: 300817883.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
Drug pricing under 340B program; Reform of 340B program;
Cancer Patient Protection;
Ongoing issues related to the implementation of the Affordable Care Act;
Comparative effectiveness research, and FDA approval of follow-on biologics; Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Reimbursement and patient access issues associated with CMMI Medicare Part B Drug Payment Model proposal and demo project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and tax extenders;
Issues relating to corporate tax reform including the R&D tax credit and taxation of foreign-owned corporations
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program;
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement;
Issues relating to Prescription Drug User Fee Act and ASP +6;
Issues related to comparative effectiveness and follow-on biologics;
Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
Drug pricing under 340B program;
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act;
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics;
HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs;
Reimbursement and patient access issues associated with CMMI proposed Medicare Part B Drug Payment Model
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
Rivendell Group LLP amended a lobbying report for representation of Genentech in Q12016 on July 20, 2016.
Original Filing: 300817960.xml
Lobbying Issues
Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
Drug pricing under 340B program; Reform of 340B program;
Cancer Patient Protection;
Ongoing issues related to the implementation of the Affordable Care Act;
Comparative effectiveness research, and FDA approval of follow-on biologics; Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to FDA & HHS program funding; FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and tax extenders;
Issues relating to corporate tax reform including the R&D tax credit and taxation of foreign-owned corporations
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to H.R. 6, the 21st Century CURES Act;
Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program;
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement;
Issues relating to Prescription Drug User Fee Act and ASP +6;
Issues related to comparative effectiveness and follow-on biologics;
Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
Drug pricing under 340B program;
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act;
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics;
HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs;
Public Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Rivendell Group LLP lobbied for Genentech , earning $30,000. The report was filed on April 15, 2016.
Original Filing: 300791691.xml
Lobbying Issues
Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
Drug pricing under 340B program; Reform of 340B program;
Cancer Patient Protection;
Ongoing issues related to the implementation of the Affordable Care Act;
Comparative effectiveness research, and FDA approval of follow-on biologics; Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to FDA & HHS program funding; FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform and tax extenders;
Issues relating to corporate tax reform including the R&D tax credit and taxation of foreign-owned corporations
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to H.R. 6, the 21st Century CURES Act;
Concerns regarding Medicare policies for Part B drugs;
Issues related to the 340B Drug discount program;
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement;
Issues relating to Prescription Drug User Fee Act and ASP +6;
Issues related to comparative effectiveness and follow-on biologics;
Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee);
Issues concerning implementation of Patient Protection and Affordable Care Act;
Drug pricing under 340B program;
Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act;
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics;
HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs;
Public Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
Rivendell Group LLP filed a lobbying registration on March 9, 2016 to represent Genentech, effective Jan. 1, 2016.
Original Filing: 300787253.xml
Issue(s) they said they’d lobby about: Concerns regarding Medicare policies for Part B drugs; 21st Century Cures Initiative; issues concerning implementation of Patient Protection and Affordable Care Act; Drug Pricing under 340B program .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...